HK36593A - Use of ketone derivatives in the treatment of depression - Google Patents

Use of ketone derivatives in the treatment of depression Download PDF

Info

Publication number
HK36593A
HK36593A HK365/93A HK36593A HK36593A HK 36593 A HK36593 A HK 36593A HK 365/93 A HK365/93 A HK 365/93A HK 36593 A HK36593 A HK 36593A HK 36593 A HK36593 A HK 36593A
Authority
HK
Hong Kong
Prior art keywords
methyl
active ingredient
compound
treatment
carbazol
Prior art date
Application number
HK365/93A
Other languages
English (en)
French (fr)
Inventor
Michael Brian Tyers
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of HK36593A publication Critical patent/HK36593A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Connection Of Batteries Or Terminals (AREA)
  • Emergency Protection Circuit Devices (AREA)
  • Electrotherapy Devices (AREA)
  • Saccharide Compounds (AREA)

Claims (6)

  1. Die Verwendung von 1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)-methyl]-4H-carbazol-4-on und der physiologisch annehmbaren Salze und Solvate davon für die Herstellung eines Arzneimittels für die Behandlung der Depression.
  2. Verwendung nach Anspruch 1 für die Herstellung eines Arzneimittels, das für die orale, bukkale, parenterale oder rektale Verabreichung geeignet ist oder für ein Depotpräparat.
  3. Verwendung nach Anspruch 1 oder 2 für die Herstellung eines Arzneimittels in Dosiseinheitsform, die 0,05 bis 20 mg an aktivem Bestandteil pro Dosiseinheit, ausgedrückt als das Gewicht der freien Base, enthält.
  4. Verwendung nach Anspruch 3, wobei die Menge an aktivem Bestandteil pro Dosiseinheit von 0,1 bis 10 mg beträgt.
  5. Verwendung nach einem der Ansprüche 1 bis 4, wobei 1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)-methyl]-4H-carbazol-4-on in Form eines Hydrochloridsalzes verwendet wird.
  6. Verwendung nach einem der Ansprüche 1 bis 4, wobei 1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)-methyl]-4H-carbazol-4-on in Form des Hydrochlorid-dihydratsalzes verwendet wird.
HK365/93A 1986-12-17 1993-04-15 Use of ketone derivatives in the treatment of depression HK36593A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868630071A GB8630071D0 (en) 1986-12-17 1986-12-17 Medicaments

Publications (1)

Publication Number Publication Date
HK36593A true HK36593A (en) 1993-04-23

Family

ID=10609112

Family Applications (1)

Application Number Title Priority Date Filing Date
HK365/93A HK36593A (en) 1986-12-17 1993-04-15 Use of ketone derivatives in the treatment of depression

Country Status (18)

Country Link
US (1) US4835173A (de)
EP (1) EP0276559B1 (de)
JP (1) JP2732844B2 (de)
KR (1) KR880007073A (de)
AT (1) ATE79031T1 (de)
AU (1) AU608794B2 (de)
CY (1) CY1693A (de)
DE (1) DE3780940T2 (de)
DK (1) DK662787A (de)
ES (1) ES2051754T3 (de)
GB (1) GB8630071D0 (de)
GR (1) GR3005682T3 (de)
HK (1) HK36593A (de)
IE (1) IE60135B1 (de)
IL (1) IL84844A0 (de)
NZ (1) NZ222949A (de)
PH (1) PH25503A (de)
ZA (1) ZA879458B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5246941A (en) * 1986-12-17 1993-09-21 Glaxo Group Limited Method for the treatment of depression
US4973594A (en) * 1986-12-17 1990-11-27 Glaxo Group Limited Medicaments
US5221687A (en) * 1988-09-01 1993-06-22 Glaxo Group Limited Medicaments
GB8820653D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
US5180728A (en) * 1989-09-25 1993-01-19 Fujisawa Pharmaceutical Company, Ltd. Pyrimidoindole derivatives and processes for preparation thereof
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
WO1993000074A1 (en) * 1991-06-26 1993-01-07 Sepracor, Inc. Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
WO2000051582A2 (en) * 1999-03-01 2000-09-08 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
EP1339707A2 (de) * 2000-10-30 2003-09-03 Teva Pharmaceutical Industries Ltd. Neue kristall- und solvatformen von ondansetronhydrochlorid und verfahren zu deren herstellung
EP1207160A1 (de) * 2000-11-20 2002-05-22 Hanmi Pharm. Co., Ltd. Verfahren zur Herstellung von 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)-methyl)-4H-carbazol-4-one
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
EP1355881A4 (de) * 2001-01-11 2004-03-31 Teva Pharma Verbessertes verfahren zur herstellung von reinem ondansetronhydrochlorid-dihydrat
PT1499623E (pt) * 2002-04-29 2007-08-10 Teva Gyogyszergyar Zartkoeruee ''processo papa a preparação de 1, 2, 3, 9-tetra-hidro-9-metil-3- [(2-metil-1h-imidazol-1-il) metil] -4h-carbazol-4-ona''
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
MXPA04010845A (es) * 2002-04-30 2005-01-25 Biogal Gyogyszergyar Formas cristalinas novedosas de ondansetron, procesos para su preparacion, composiciones farmaceuticas que contienen las formas novedosas y metodos para tratar las nauseas utilizando las mismas.
HU225885B1 (en) * 2002-10-17 2007-11-28 Richter Gedeon Nyrt Process for producing ondansetron hydrochlorid dihydrate of high purity
EP2186517A4 (de) * 2007-08-08 2010-08-18 Ibanez Juan Jose Legarda Verwendung und anwendungsverfahren für einen serotin3-rezeptor (5-ht3)-antagonisten und selektiven chloridkanalmodulator zur behandlung von sucht bzw. abhängigkeit von arzneimitteln/drogen oder erkrankungen des nervensystems
EP3810120A2 (de) 2018-06-21 2021-04-28 Société des Produits Nestlé S.A. Zusammensetzungen und verfahren unter verwendung eines nicotinamid-adenin-dinucleotides (nad+)-vorläufers und mindestens eines ketons oder keton-vorläufers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN158970B (de) * 1981-06-09 1987-02-28 Ici Plc
LU88268I2 (de) * 1984-01-25 1994-02-03
GB8401888D0 (en) * 1984-01-25 1984-02-29 Glaxo Group Ltd Heterocyclic compounds
DE201165T1 (de) * 1985-03-14 1989-04-20 Beecham Group P.L.C., Brentford Arzneimittel zur behandlung von emesis, anxietas und "irritable bowel syndrome".
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8518743D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds
HU895334D0 (en) * 1986-07-30 1990-01-28 Sandoz Ag Process for the preparation of nasal pharmaceutical compositions

Also Published As

Publication number Publication date
PH25503A (en) 1991-07-24
KR880007073A (ko) 1988-08-26
DE3780940D1 (de) 1992-09-10
ZA879458B (en) 1988-11-30
CY1693A (en) 1994-01-14
US4835173A (en) 1989-05-30
IE873415L (en) 1988-06-17
JP2732844B2 (ja) 1998-03-30
IE60135B1 (en) 1994-06-01
EP0276559A3 (en) 1989-10-18
DK662787D0 (da) 1987-12-16
IL84844A0 (en) 1988-06-30
DK662787A (da) 1988-06-18
EP0276559B1 (de) 1992-08-05
EP0276559A2 (de) 1988-08-03
ATE79031T1 (de) 1992-08-15
GR3005682T3 (de) 1993-06-07
GB8630071D0 (en) 1987-01-28
NZ222949A (en) 1997-06-24
AU8261787A (en) 1988-06-23
AU608794B2 (en) 1991-04-18
ES2051754T3 (es) 1994-07-01
JPS63165314A (ja) 1988-07-08
DE3780940T2 (de) 1992-12-24

Similar Documents

Publication Publication Date Title
EP0276559B1 (de) Verwendung von Ketonderivaten zur Behandlung von Depressionen
IE60908B1 (en) Pharmaceutical compositions for treating gastric disorders
EP0275668B1 (de) Verwendung von Ketonderivaten zur Behandlung von Bewusstseinsstörungen
EP0278161B1 (de) Ketonderivate als Arzneimittel zur Behandlung oder Vorbeugung des Entzugssyndromes
US6569883B1 (en) Medicaments
EP0411900A2 (de) Arzneimittel zur Behandlung von Bulimie
CA1330536C (en) Medicament for the treatment of a cognitive disorder
EP0269452A2 (de) Anwendung von Keton-Derivaten zur Herstellung von Arzneimitteln
US5229407A (en) Medicaments
AU627768B2 (en) The use of lactam derivatives in the treatment of addiction
US5221687A (en) Medicaments
AU627770B2 (en) The use of lactam derivatives in the treatment of depression
JPH01250319A (ja) 医薬

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20041216